HUTCHMED (China) Limited HCM
13.99 USD 0.00 (+0.00%)
Regular-session close
14.90 +0.91 +6.50%
Pre-market · Nov 19, 8:05 AM ET
Day range unavailable
9.77 52-week range 16.33
- YTD
- +4.95%
- 1 year
- -4.57%
News
benzinga.com HUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase Immune Thrombocytopenia ("ITP"): For the treatment of adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy; andWarm Antibody Autoimmune…
globenewswire.com HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia — SYVIK ® becomes the first novel Syk inhibitor approved in China —
globenewswire.com HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics — A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —
globenewswire.com HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal…
seekingalpha.com HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcriptbenzinga.com Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent…
benzinga.com Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
benzinga.com HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned — ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…
benzinga.com HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…
